CAJ | 학술논문

目的:切除修复交叉互补基因1(exsicion repair cross-complementing group 1,ERCC1)和核糖核苷酸还原酶M1(ribonu?cleotide reductase M1,RRM1)的表达水平可预测非小细胞肺癌(non-small cell lung cancer,NSCLC)对化疗的敏感性.旨在评价免疫组织化学检测的蛋白水平与液相芯片检测的mRNA水平的临床应用价值.方法:采用免疫组织化学和液相芯片方法分别检测42例非小细胞肺癌组织中ERCC1、RRM1的蛋白表达和mRNA表达水平,非参数相关性分析二者表达的相关性.结果:两种方法检测的非小细胞肺癌组织中ERCC1和RRM1蛋白表达与mRNA表达的一致率分别为52.3%(22/42)和76.2%(32/42);两种方法检测RRM1和ERCC1蛋白表达和mRNA表达呈正相关(r=0.778,P=0.010;r=0.277,P=0.076).结论:免疫组织化学检测的RRM1和ERCC1的蛋白水平与液相芯片检测的mRNA水平具有较好的一致性和相关性,二种方法同时检测可以增加临床应用的敏感性和特异性.
목적:절제수복교차호보기인1(exsicion repair cross-complementing group 1,ERCC1)화핵당핵감산환원매M1(ribonu?cleotide reductase M1,RRM1)적표체수평가예측비소세포폐암(non-small cell lung cancer,NSCLC)대화료적민감성.지재평개면역조직화학검측적단백수평여액상심편검측적mRNA수평적림상응용개치.방법:채용면역조직화학화액상심편방법분별검측42례비소세포폐암조직중ERCC1、RRM1적단백표체화mRNA표체수평,비삼수상관성분석이자표체적상관성.결과:량충방법검측적비소세포폐암조직중ERCC1화RRM1단백표체여mRNA표체적일치솔분별위52.3%(22/42)화76.2%(32/42);량충방법검측RRM1화ERCC1단백표체화mRNA표체정정상관(r=0.778,P=0.010;r=0.277,P=0.076).결론:면역조직화학검측적RRM1화ERCC1적단백수평여액상심편검측적mRNA수평구유교호적일치성화상관성,이충방법동시검측가이증가림상응용적민감성화특이성.
Objective:With the treatment of non-small cell lung cancer (NSCLC) entering the era of individualization through the detection of expression levels of promising biomarkers in NSCLC tumor samples, tailored chemotherapy, and prognosis evaluation for NSCLC patients are now possible. This study focuses on two commonly utilized detection methods:immunohistochemistry (IHC) and suspension biochip. This study aims to determine the differences between IHC and suspension biochip with regard to the expres-sion levels of biomarkers. Methods:Forty-two NSCLC patients were enrolled into the study from April 2011 to June 2012. The expres-sion levels of excision repair cross-complementing group 1(ERCC1) and ribonucleotide reductase (RRM1) in the tumor samples were tested through IHC and suspension biochip, respectively. The statistical methods used in the analysis were were performed with the SPSS (version 17.0) statistical software;P<0.05 was considered statistically significant. Results:The consistent rates of the ERCC1 and RRM1 expression levels tested by IHC and suspension biochip were 52.3%(22/42) and 76.2%(32/42), respectively. A significant correlationship was observed between IHC and suspension biochip in terms of the RRM1 expression levels (r=0.778, P=0.01). No such correlationship was found in the ERCC1 expression levels (r=0.277, P=0.076). Conclusion:The expression levels of RRM1 tested by the two methods exhibited good correlationship. The expression levels of the RRM1 mRNA in the NSCLC tissues were consistent with RRM1 protein expression. No significant correlationship was found in the expression levels of ERCC1 tested by the two methods. The expression levels of the ERCC1 mRNA in the NSCLC tissues were not always correlated with ERCC1 protein expression. The simulta-neous use of IHC and suspension biochip can increase the sensitivity and specificity of chemotherapy.